Acute Myeloid Leukemia
Conditions
Brief summary
The purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options.
Detailed description
The purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options. The objective of our program of research is to ultimately improve understanding about what patients with Acute Myeloid Leukemia (AML) know and understand about their disease, as well as what kind of information AML patients want or need to further inform them about the treatment decisions they face. The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path. Recruited subjects will complete a series of surveys, both before viewing of the videos and after
Interventions
OTHERElectronic Decision Aid Tool
The AML Decision Aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what AML is, treatment choices, and things to consider when determining a treatment path.
Sponsors
American Cancer Society, Inc.
Duke University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
For this study, we will test the feasibility and preliminary efficacy of utilizing a novel electronic decision aid to improve AML patients' understanding of their illness, prognosis, and treatment options.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* At least age 18 * Capacity to give consent * Diagnosis of acute myeloid leukemia (AML) * Fluent in English * Receiving care at Duke, and fits into one of the following scenarios: * has not yet made a treatment decision (in the DCI clinics or on the inpatient wards), * have recently made a decision (in the last 6 weeks), and are admitted for chemotherapy on 9100 or in the oncology treatment center to receive outpatient therapy, * or, during remission, while receiving consolidation chemotherapy in the hospital
Exclusion criteria
* Patients too sick to participate per clinician discretion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of enrolled subjects who have completed the study | 1 day | Feasibility will be determined by enrolled subjects who complete the study (including watching all videos, and completing the surveys). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in knowledge about AML after video viewing | Day 1. Pre-video screening and post-video | Efficacy will be measured by change in knowledge about AML, (including knowledge about the disease itself, and comprehending AML treatment choices and their risks, as measured through changes in AML Knowledge Questionnaire scores) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes in Attitudes Towards Chemotherapy Scale scores | Day 1. Pre-video screening and post-video | Changes in Attitudes Towards Chemotherapy Scale scores, |
| Changes in Decisional Conflict Scale scores | Day 1. Pre-video screening and post-video | Changes in Decisional Conflict Scale scores |
| Changes in Anxiety Scores | Day 1. Pre-video screening and post-video | Changes in Anxiety Scores |
Countries
United States
Outcome results
None listed